GlassScriptPhysician profile
Alpa S Patel
NPI 1528081098
$11,637.43
in general payments reported to CMS, 2019-2025
28 companies · $2,307 in 2025
The $2,307 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $196 · 2021: $1,284 · 2022: $2,461 · 2023: $2,110 · 2024: $2,447 · 2025: $2,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,864.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,864.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $9,580.17 | 2019-2025 | Clareon, Hydrus Microstent, Unity |
| Astellas Pharma US INC | $249.77 | 2024-2025 | Izervay |
| Bausch & Lomb Americas INC. | $244.69 | 2023-2024 | Xiidra, Miebo, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $219.41 | 2019-2021 | |
| Abbvie INC. | $171.05 | 2023-2024 | |
| Glaukos Corporation | $165.63 | 2019 | |
| Kala Pharmaceuticals, INC. | $124.99 | 2022 | |
| Allergan, INC. | $122.59 | 2022 | |
| Edwards Lifesciences Corporation | $120.42 | 2021 | |
| Ivantis, INC | $96.31 | 2020-2021 | |
| Horizon Therapeutics Plc | $94.39 | 2022 | |
| Oyster Point Pharma, INC. | $62.18 | 2022 | |
| Alcon Research LLC | $57.40 | 2023 | Acrysof Iq Panoptix Uv Iol |
| Novartis Pharmaceuticals Corporation | $43.64 | 2020-2023 | |
| Johnson & Johnson Surgical Vision, INC. | $29.55 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $29.44 | 2024 | Columvi, Polivy, Lunsumio |
| Sun Pharmaceutical Industries INC. | $27.69 | 2019 | |
| Coherus Oncology, INC. | $24.82 | 2023 | |
| Ani Pharmaceuticals, INC. | $21.35 | 2025 | Iluvien |
| Shire North American Group INC | $19.79 | 2019 | |
| Ocular Therapeutix, INC. | $19.00 | 2021 | |
| Sight Sciences, INC. | $18.01 | 2021 | |
| Eisai INC. | $17.60 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Glaxosmithkline, LLC. | $15.65 | 2024 | Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $15.60 | 2025 | Eylea Hd |
| Revance Therapeutics, INC. | $15.07 | 2024 | Daxxify |
| Beaver-Visitec International, INC. | $13.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alpa Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.